Christina Wu, Reetesh K Pai, Heidi Kosiorek, Imon Banerjee, Ashlyn Pfeiffer, Catherine E Hagen, Christopher P Hartley, Rondell P Graham, Mohamad B Sonbol, Tanios Bekaii-Saab, Hao Xie, Frank A Sinicrope, Bhavik Patel, Thomas Westerling-Bui, Sameer Shivji, James Conner, Carol Swallow, Paul Savage, David P Cyr, Richard Kirsch, Rish K Pai
PURPOSE: There is a need to improve current risk stratification of stage II colorectal cancer (CRC) to better inform risk of recurrence and guide adjuvant chemotherapy. We sought to examine whether integration of QuantCRC, a digital pathology biomarker utilizing hematoxylin and eosin-stained slides, provides improved risk stratification over current American Society of Clinical Oncology (ASCO) guidelines. EXPERIMENTAL DESIGN: ASCO and QuantCRC-integrated schemes were applied to a cohort of 398 mismatch repair proficient (MMRP) stage II CRCs from three large academic medical centers...
February 29, 2024: Clinical Cancer Research